On Sunday, April 20th 2025, starting 8:30am GMT, there will be maintenance work that will involve the website being unavailable during parts of the day. We apologize for any inconvenience this may cause and appreciate your understanding.
We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Principles in Bacterial Pathogenesis
-
1. The molecular basis of bacterial pathogenicity: an overview
- Prof. B. Brett Finlay
- Gram Negative Pathogens
-
2. Deciphering shigella invasion of epithelial cells
- Prof. Philippe Sansonetti
-
5. Bordetella pertussis
- Prof. Alison Weiss
-
6. Salmonellae: molecular basis of infection
- Prof. Samuel Miller
-
7. The diversity of Escherichia coli infections
- Prof. Michael Donnenberg
-
8. Bacterial activation of epithelial signaling
- Prof. Alice Prince
-
9. Human pathogenic Yersinia species
- Prof. James Bliska
-
11. Dental pathogens
- Prof. Ann Progulske-Fox
-
12. Haemophilus
- Prof. Robert Munson
- Gram Positive Pathogens
-
13. The bacterial pathogen Listeria monocytogenes: an amazing multifaceted model
- Prof. Pascale Cossart
-
15. Molecular pathogenesis and prevention of Staphylococcus aureus infections
- Prof. Olaf Schneewind
-
16. Streptococcus pyogenes disease and molecular pathogenesis
- Prof. P. Patrick Cleary
- Host Responses
-
17. Microbial recognition and the immune response
- Dr. Dana Philpott
-
18. Enteric pathogens-microbiota-host inter-kingdom chemical interactions
- Prof. Vanessa Sperandio
-
19. Toll-like receptor signalling during infection and inflammation
- Prof. Luke O'Neill
-
20. The human indigenous microbiota
- Prof. David Relman
-
22. Role of neutrophils in acute lung injury and repair
- Prof. Gregory Downey
- Preventatives and Therapeutics
-
23. Antibiotics and antibiotic resistance
- Prof. Gerry Wright
-
24. Vaccines: a health insurance of the 21st century
- Prof. Rino Rappuoli
-
25. Biodefense vaccines
- Prof. James Nataro
- Archived Lectures *These may not cover the latest advances in the field
-
26. Vaccines in the modern world
- Prof. Gordon Dougan
-
27. Bacterial infection of epithelial signaling
- Prof. Alice Prince
Printable Handouts
Navigable Slide Index
- Introduction
- Outline
- What are vaccines?
- What are vaccines composed of?
- Vaccines in common use today
- Type of immune response induced by vaccination
- Introduction of vaccines and disease incidence
- Vaccination is not popular with everyone
- The trend towards defined vaccines
- Developing a safer whooping cough vaccine
- Smallpox: the first vaccine
- Risks associated with smallpox vaccination
- A vaccine campaign used to eradicate smallpox
- Example - vaccines against polio
- Inactivated vs. live attenuated
- Example: vaccines against meningitis
- Neisseria meningitidis - pathogenesis
- Vaccines based on the meningococcal capsules
- Conjugated vaccines
- Meningitis C conjugate vaccine in the late 1990s
- The meningococcal B capsule is not immunogenic
- 'Mining' men B genome using 'reverse vaccinology'
- 350 menB proteins used for mice immunization
- 28 novel antigens with bactericidal activity
- Antigenic composition of the Novartis vaccine
- Novartis vaccine is immunogenic in infants
- Edible vaccines
- Vaccines can now be based on DNA
- Final comments
Topics Covered
- What are vaccines?
- Vaccine composition
- Vaccines in common use
- Type of immune response induced by vaccination
- Impact on disease incidence
- Smallpox: the first vaccine
- Vaccines against polio and meningitis
- What is a conjugated vaccine
- Reverse vaccinology
- Novartis MenB protein vaccine
- Vaccines can now be based on DNA
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Dougan, G. (2009, October 29). Vaccines in the modern world [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 19, 2025, from https://doi.org/10.69645/FODO2757.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Gordon Dougan has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Infectious Diseases
Transcript
Please wait while the transcript is being prepared...
0:00
My name is
Professor Gordon Dougan.
And I work at the Wellcome
Trust Sanger Institute
at the University of Cambridge
in Cambridge, England.
I am currently head of pathogen
research at the Sanger.
But for many years,
I worked in industry.
During that time, I was
involved in vaccine discovery,
development, and production.
0:23
Today, I'm going to talk
to you about how I believe
vaccines fit into the modern world.
To achieve that, we'll start off
by talking about what vaccines are.
We'll then talk about how vaccines
are made and what they're made of.
I'll talk to you a little
bit about how they work.
But then I'll go through a number of
specific examples of real vaccines.
We'll start off with vaccines
which are well established.
And many of them, you will
have heard of and might
even have received yourself.
We'll talk about vaccines, which are
in the development phase, which are
being prepared for sale,
but they're not quite there
yet, and might cover new diseases.
And I'll finish off by talking
about emerging technologies
and how these technologies might
transform vaccines in the future.
I feel that we're in a very exciting
period for vaccine research.
We call this field the area
of vaccinology at the moment.
And I'll try and get across
to you during this lecture
why I feel there are so many
opportunities in the field.
1:26
What are vaccines?
Vaccines are used to prevent
disease by stimulating immunity.
But they do this
without causing disease.
They are normally made from either
live attenuated microorganisms
or their nonliving components.
By attenuated, we mean live
organisms that have been modified,
so that they do not cause disease.
But they can still
stimulate immunity.
Now, vaccines are used
prophylactically in healthy people.
That means, we use in
before people actually
get ill, unlike normal drugs.
Now, vaccines can
theoretically be used
therapeutically to treat disease.
But so far, we don't have any
licensed therapeutic vaccines.
Molecular sciences are
revolutionizing our understanding
of infection and immunity.
And this is triggering a golden
age of vaccine development.
We've had more new vaccines
made in the last 10 to 15 years
than in the previous 100.
A good example is the new
vaccine against papilloma
or cervical cancer.
So the important
point really here is
that vaccines are used to prevent
disease before disease starts.
And this distinguishes
them from drugs.